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ABSTRACT A clinically reflective model of the human colon was used to investigate
the effects of the broad-spectrum antibiotic omadacycline on the gut microbiome
and the subsequent potential to induce simulated Clostridium difficile infection (CDI).
Triple-stage chemostat gut models were inoculated with pooled human fecal slurry
from healthy volunteers (age, 60 years). Models were challenged twice with 107
CFU C. difficile spores (PCR ribotype 027). Omadacycline effects were assessed in a
single gut model. Observations were confirmed in a parallel study with omadacy-
cline and moxifloxacin. Antibiotic instillation was performed once daily for 7 days.
The models were observed for 3 weeks postantibiotic challenge. Gut microbiota
populations and C. difficile total viable and spore counts were enumerated daily by
culture. Cytotoxin titers and antibiotic concentrations were also measured. Gut mi-
crobiota populations were stable before antibiotic challenge. Moxifloxacin instillation
caused an 4 log10 CFU/ml decline in enterococci and Bacteroides fragilis group
populations and an 3 log10 CFU/ml decline in bifidobacteria and lactobacilli, fol-
lowed by simulated CDI (vegetative cell proliferation and detectable toxin). In both
models, omadacycline instillation decreased populations of bifidobacteria (8 log10
CFU/ml), B. fragilis group populations (7 to 8 log10 CFU/ml), lactobacilli (2 to 6 log10
CFU/ml), and enterococci (4 to 6 log10 CFU/ml). Despite these microbial shifts, there
was no evidence of C. difficile bacteria germination or toxin production. In contrast
to moxifloxacin, omadacycline exposure did not facilitate simulated CDI, suggesting
this antibiotic may have a low propensity to induce CDI in the clinical setting.
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Clostridium difficile infection (CDI) is the leading cause of nosocomial antibiotic-associated diarrhea around the world and a major cause of morbidity in the
hospitalized elderly (1).
A stable gut microbiota provides colonization resistance, a key factor in preventing
C. difficile colonization and proliferation (2). Antibiotic use is a substantial risk factor for
CDI due to the disruption of the microbiota. In particular, broad-spectrum antibiotics
(e.g., fluoroquinolones, cephalosporins, and clindamycin) represent an increased CDI
risk, especially when they are associated with the protracted impairment of microbiota
populations (3, 4).
Omadacycline is a potent aminomethylcycline, with in vitro activity against Gram-
positive and Gram-negative bacteria, including methicillin-susceptible and -resistant
Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, Entero-
coccus faecium, Streptococcus pneumoniae, Klebsiella pneumoniae, and Bacteroides fra-
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gilis (5, 6). Omadacycline has recently completed phase 3 clinical trials for acute
bacterial skin and skin structure infections and community-acquired bacterial pneumo-
nia (7). Similar to other tetracyclines, omadacycline inhibits protein synthesis by binding
to the 30S ribosomal subunit, although this novel antimicrobial has been structurally
modified to overcome efflux mechanisms (6, 8). The effect of omadacycline on the
normal gut microbiome and its subsequent potential for the induction of CDI have not
been investigated.
The in vitro gut model has been previously used to study antibiotic predisposition
to simulated CDI using epidemic virulent strains, and the results appear to correlate
well with clinical CDI risk (9). Antibiotics known to have a high propensity to induce CDI
clinically have induced CDI in this model (9–12). Conversely, piperacillin-tazobactam
and tigecycline, antibiotics with a low propensity to induce CDI, did not promote C.
difficile germination and toxin production in the gut model (13, 14).
This study investigated the effects of omadacycline instillation on the normal gut
microbiome populations and the subsequent potential for induction of CDI compared
with those of moxifloxacin.
RESULTS
Effects of omadacycline instillation on gut microflora and C. difficile popula-
tions. A single triple-stage chemostat model (see Fig. S1 in the supplemental material)
containing a stable microbiota derived from healthy stool samples was used to inves-
tigate the effects of omadacycline on the colonic microflora and the propensity of the
antibiotic to induce simulated CDI. This gut model, here referred to as OMC, was
instilled with a clinically reflective regimen of omadacycline, and microbial populations,
including Clostridium difficile total counts and spores, were monitored daily. The
changes in gut microbial populations in vessels 2 and 3 were similar during omada-
cycline instillation. Vessel 3 is of most clinical relevance for CDI (see Materials and
Methods). Results of bacterial enumeration in vessel 3 are shown in Fig. 1, whereas
vessel 2 data are presented as supplemental material (see Fig. S2). Omadacycline
instillation caused a decline of 7 log10 CFU/ml in B. fragilis group bacteria (standard
error [SE], 0.16) and a decline of 8 log10 CFU/ml in bifidobacteria populations (SE,
0.14). Both of these bacterial populations decreased to below the limit of detection
(1.2 log10 CFU/ml) in vessel 3 (Fig. 1a). Enterococcus spp. (SE, 0.18) and lactobacilli
(SE,  0.1) decreased 4 log10 CFU/ml and 2 log10 CFU/ml, respectively (Fig. 1b).
Lactose-fermenting Enterobacteriaceae populations (SE, 0.18) increased during om-
adacycline exposure, between 2 log10 CFU/ml in vessel 2 and 1 log10 CFU/ml in vessel
3. Overall, a 2-log decrease in total viable counts (SE, 0.18) was observed following
omadacycline exposure, whereas total facultative anaerobic populations (SE, 0.25)
remained stable. The recovery of gut microbiota populations was observed 7 days after
omadacycline instillation ended, and populations had returned to steady-state levels by
the end of the experiment.
C. difficile total viable counts (TVCs; SE, 0.17) remained roughly equal to spore
counts (SE, 0.23; as distinguished by alcohol tolerance) throughout the experiment in
all three vessels of OMC, indicating that all C. difficile bacteria remained as spores (vessel
3 data shown in Fig. 1c; for vessel 2 data, see Fig. S2c in the supplemental material).
Vegetative cell proliferation was not observed, and toxin was not detected in any of the
vessels. Simulated CDI did not occur in the OMC gut model.
In OMC, the mean bioactive omadacycline concentrations peaked at 384 (SE, 64.8)
mg/liter, 163 (SE, 30.3) mg/liter, and 85 (SE, 46.7) mg/liter in vessels 1, 2 and 3,
respectively. Antimicrobial concentrations in OMC were detectable for 2, 3, and 5 days
in vessels 1, 2, and 3, respectively, in the postantibiotic period.
In vitro comparison of omadacycline and moxifloxacin propensity to induce
CDI. Following the observation that omadacycline did not induce simulated CDI in
model OMC, a pair of gut models comparing omadacycline (OMC1) and moxifloxacin
(MOX) exposure was run. Moxifloxacin has previously been shown to induce simulated
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FIG 1 Mean obligate anaerobic gut microbiota populations (log10 CFU/ml) (a); mean facultative anaer-
obic gut microbiota populations (log10 CFU/ml) (b); and mean C. difficile total viable counts and spore
counts (log10 CFU/ml), cytotoxin titers (relative units, RU), and antimicrobial concentration (mg/liter) (c)
in vessel 3 of model OMC. All vertical arrows mark the addition of C. difficile spores to the model, and
horizontal arrow marks the period of antibiotic instillation. LF Enterobacteriaceae, lactose-fermenting
Enterobacteriaceae; LoD, limit of detection.
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CDI in the in vitro gut model (12) and has been linked to the spread of the epidemic
027 ribotype (15).
Again, population changes in vessel 2 and vessel 3 were similar, so vessel 3 data only
are shown in Fig. 2 and 3, whereas vessel 2 data are presented in Fig.S3 and S4 in the
supplemental material. The addition of C. difficile spores to the gut models did not
cause any variations in the intestinal bacterial populations monitored in OMC1
and MOX.
In OMC1, omadacycline exposure caused declines in B. fragilis group bacteria (SE,
0.11) and bifidobacteria (SE, 0.24) of 8 log10 CFU/ml, to below the limit of
detection (Fig. 2a). Lactobacilli (SE, 0.20) and Enterococcus spp. (SE, 0.25) popula-
tions declined by 6 log10 CFU/ml (Fig. 3a), and lactose-fermenting Enterobacteriaceae
populations (SE, 0.099) decreased approximately 5 log10 CFU/ml. Overall, omada-
cycline instillation in OMC1 led to a decrease of 5 log10 CFU/ml in the total viable
counts (SE, 0.2), although the total facultative anaerobic populations (SE, 0.18)
remained fairly stable throughout the experiment, suggesting a decline of the obligate
FIG 2 Mean obligate anaerobic gut microbiota populations (log10 CFU/ml), including standard error bars,
in vessel 3 of model OMC1 (omadacycline dosing) (a) and model MOX (moxifloxacin dosing) (b).
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anaerobic populations. Gut microbiota had returned to steady-state levels by the end
of the experiment, with the initial recoveries being observed 9 days after omadacycline
instillation ended.
Moxifloxacin instillation caused marked declines in B. fragilis group populations (SE,
0.1), between 4 log10 CFU/ml in vessel 3 (Fig. 2b) and 8 log10 CFU/ml in vessel 2
(see Fig. S3b). Populations of bifidobacteria (SE, 0.18) and lactobacilli (SE, 0.1)
declined 3 log10 CFU/ml in both vessels 2 and 3 (Fig. 2b and 3b; see also Fig.S3b and
S4b). Enterococci populations (SE, 0.18) also decreased 4 log10 CFU/ml in both
vessels. Lactose-fermenting Enterobacteriaceae populations (SE, 0.18) remained stable
in vessel 3 but declined 2 log10 CFU/ml in vessel 2 (Fig. 3b; see also Fig. S4b). Overall,
both obligate (SE, 0.14) and facultative anaerobes (SE, 0.19) remained constant
during and after moxifloxacin instillation, as suggested by the total viable counts.
Microbiota populations returned to steady-state numbers approximately 1 week after
moxifloxacin instillation ended (Fig. 2b and 3b).
FIG 3 Mean facultative anaerobic gut microbiota populations (log10 CFU/ml), including standard error bars, in
vessel 3 of model OMC1 (omadacycline dosing) (a) and model MOX (moxifloxacin dosing) (b). LF Enterobacteriaceae,
lactose-fermenting Enterobacteriaceae.
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Effect of omadacycline and moxifloxacin on C. difficile. As was observed in OMC,
TVCs (SE, 0.09) in OMC1 remained similar to spore counts (SE, 0.17) throughout the
experiment in all vessels. C. difficile vegetative cell proliferation was not observed, and
toxin was not detected (Fig. 4a; see also Fig. S5a).
In all vessels of the MOX gut model, C. difficile remained as spores during the internal
control stage (period B); however, during moxifloxacin instillation (period C), an in-
crease in TVCs (SE, 0.16) compared with spore counts (SE, 0.16) was observed,
corresponding to spore germination and vegetative cell proliferation. TVCs peaked at
4.2 log10 CFU/ml on day 30 in vessel 1 (data not shown) and 6 log10 CFU/ml in
vessel 2 (see Fig. S5b) and vessel 3 at day 33 (Fig. 4b). The increase in TVCs was
concomitant with the detection of C. difficile cytotoxin, which reached a peak titer of 2
FIG 4 Mean C. difficile total viable counts and spore counts (log10 CFU/ml), cytotoxin titers (relative units, RU), and
antimicrobial concentration (mg/liter) in vessel 3 of model OMC1 (omadacycline dosing) (a) and model MOX
(moxifloxacin dosing) (b). Periods A to D are defined in Fig. 5. Vertical arrows mark the addition of C. difficile spores
to the model, and horizontal arrow marks the period of antibiotic instillation. LoD, limit of detection.
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relative units in vessel 1 and 3 relative units in vessels 2 and 3. Both TVCs and toxin
titers decreased toward the end of the experiment, with toxin undetectable in all
vessels by day 42.
Antimicrobial concentrations in the gut models. Omadacycline concentrations in
OMC1 peaked at 242 (SE, 41) mg/liter, 119 (SE, 11.47) mg/liter, and 48 (SE, 2.78)
mg/liter in vessels 1, 2, and 3, respectively. Omadacycline remained detectable for 2
days in vessels 1 and 2 (vessel 2 data are shown in Fig. S5a) and for 3 days in vessel 3
(Fig. 4a) after antibiotic instillation ceased.
Moxifloxacin concentrations peaked at 55 (SE, 5.2) mg/liter, 34 (SE, 2.3) mg/liter,
and 25 (SE, 3.3) mg/liter in vessels 1, 2, and 3, respectively, and remained detectable
for 2 days in the postantibiotic period in vessels 1 and 2 (vessel 2 data are shown
in Fig. S5b), and for 3 days in vessel 3 (Fig. 4b).
DISCUSSION
The instillation of omadacycline did not elicit simulated CDI in an in vitro triple-stage
chemostat model (OMC). To further confirm OMC gut model observations, a second
experiment was conducted, where an omadacycline gut model (OMC1) was run in
parallel with a model dosed with moxifloxacin (MOX) in order to compare the potential
of each antibiotic to induce simulated CDI. Despite the fact that gut microbiota
dysbiosis appeared more severe following omadacycline exposure, C. difficile germina-
tion and toxin production (simulated CDI) were observed only in the model instilled
with moxifloxacin. The use of different fecal emulsions to initiate OMC and OMC1 aimed
to analyze the effect of the antimicrobial in unrelated human intestinal microbiota.
Similar to expected variation in different individuals, variations in the extent of the
microflora disruption were observed in OMC and OMC1; however, CDI was not ob-
served in either of the models.
Omadacycline effects on the anaerobic gut microbiota populations were similar in
OMC and OMC1, with all measured anaerobic populations affected, most notably
bifidobacteria and B. fragilis group bacteria, which declined to below the limit of
detection. The main differences between these models were observed during antimi-
crobial instillation (period C) in facultative anaerobic populations. An increase of 1
log10 CFU/ml in Enterobacteriaceae populations was observed in OMC, in opposition to
the 5 log10 CFU/ml decline observed in OMC1. This variation is likely to be associated
with the different fecal slurry used to initiate each model. A study investigating 8,345
clinical Enterobacteriaceae isolates has reported MICs to omadacycline ranging from
0.25mg/liter (4.1%) to 32mg/liter (3.4%) (16). Given the complexity of the normal
microbiota, the presence of Enterobacteriaceae strains with a wide range of suscepti-
bilities to omadacycline could explain the differences observed in these populations
during antibiotic instillation in the gut model. Compared with omadacycline, moxi-
floxacin instillation caused a less pronounced decline in B. fragilis group bacteria,
enterococci, and lactobacilli populations in vessels 2 and 3, but this was followed by the
detection of toxin in all three vessels. These findings are consistent with previous data
(12).
In a phase 1 clinical trial, omadacycline metabolism and recovery rates were
investigated in healthy individuals, following the ingestion of the recommended daily
oral dose of 300 mg of the antimicrobial (7, 17). Approximately 95% of the antimicrobial
was excreted, predominantly through feces (mean, 81.1%) and urine (14.4%), without
drug metabolites being detected. The highest concentration of omadacycline regis-
tered in human feces in that study was 430 mg/Kg (unpublished data), which
informed the use of a 430 mg/liter once daily dosing regimen in this study. Peak
omadacycline levels observed in vessel 3 were lower than 430 mg/liter, potentially
suggesting the occurrence of drug metabolism or sequestration. The lack of metabo-
lites observed in the feces clinically (17) indicates that sequestration into the biofilm is
more likely. Observed omadacycline concentrations were higher than those deter-
mined during moxifloxacin dosing. Moxifloxacin concentrations observed in vessels 1,
2, and 3 were consistent with the values reported in previous moxifloxacin gut models
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(12) and are reflective of gut levels seen in vivo (18). Microbial recovery in either OMC
model was observed between 7 and 9 days postcessation of omadacycline.
The observations in our triple-stage model have been shown to correlate with
clinical observations of antimicrobial propensity to induce CDI in vivo (9–14) and have
changed United Kingdom national antibiotic prescribing guidelines (19). Antibiotics,
such as cephalosporins (9), clindamycin (10), co-amoxyclav (11), or fluoroquinolones
(12), known to have a high propensity to induce CDI clinically, have induced CDI in this
model. Similarly, piperacillin-tazobactam (13) and tigecycline (14), two antibiotics con-
sidered of low risk for CDI clinically, have not induced simulated CDI in the gut model.
An intact colonic microbiota has an important role in protecting the organism against
intestinal bacterial pathogens (2, 20). Broad-spectrum antibiotic therapy causes a
decline of the commensal microflora, leading to a diminution of microbiota diversity
and the subsequent opportunity for the outgrowth of pathogens, such as C. difficile (3,
4). Notably, the gut model studies that investigated piperacillin-tazobactam (13) and
tigecycline (14) also observed a significant decrease in intestinal microflora populations
and yet an absence of induction of CDI. The tigecycline MIC of the PCR ribotype 027
strain used in this study was 0.06 mg/liter, with tigecycline concentrations remaining
above 1 mg/liter 5 days after cessation of antibiotic instillation (14).
In the present study, the omadacycline MIC (0.25 mg/liter) of the C. difficile strain
added to the gut model was assessed by the recommended agar dilution method (21)
(data not shown). C. difficile ATCC 700057 (MIC, 1 mg/liter) was used as a control (22).
Omadacycline levels dropped to below the limit of detection (8 mg/liter) at day 34 and
32, in OMC and OMC1, respectively. While the bioactive concentration of omadacycline
remains higher than the strain MIC, it would be expected that any C. difficile spore
outgrowth would be prevented; however, once the concentrations decrease below the
MIC, spore outgrowth and vegetative cell proliferation would no longer be prevented.
This is observed following clindamycin exposure in the gut model. A C. difficile strain
with a clindamycin MIC of 0.5 mg/liter does not germinate during clindamycin instil-
lation (10), but CDI is consistently observed in the postantibiotic period. Once clinda-
mycin levels fall below the limit of detection (typically around 5- to 7-days postinstil-
lation), C. difficile vegetative proliferation and toxin are observed. It is possible that
omadacycline, tigecycline, and piperacillin-tazobactam intrinsic activity against C. dif-
ficile persists long enough to prevent its proliferation, even when a potential niche has
been created by antibiotic exposure. Baines et al. (13) have previously proposed that
the biofilm formed on the walls of the vessels may contribute to the swift recovery of
the bacterial populations in the gut model and operates as a bacterial reservoir during
antimicrobial dosing. It is possible that the biofilm formed in the chemostat model can
also contribute to the persistence of the drug to a concentration higher than 0.25
mg/liter, sufficient to inhibit C. difficile spore germination and, therefore, prevent
simulated CDI in the gut model. The sequestration of fidaxomicin into the biofilm of the
gut model has previously been observed and hypothesized to contribute to the
prolonged detection of fidaxomicin in the gut model and patient stool (23). Moreover,
the relatively rapid reconstitution of gut microflora populations after the cessation of
antimicrobial instillation will provide further protection against CDI.
Despite the disruptive effects of omadacycline to the colonic microflora, compared
with the present and previous gut model studies, our data suggest that omadacycline
may have a lower-risk for CDI induction than moxifloxacin and other fluoroquinolones.
These observations agree with published studies focusing on the impact of antibiotic
exposure on CDI risk in hospital (24) and community settings (25), which reported
tetracyclines to be among the classes of antimicrobials with the lowest risk for CDI
induction (26). Furthermore, in a recent phase 3 community-acquired pneumonia
clinical trial, there were no cases of CDI observed in patients treated with omadacycline,
compared with eight cases (2%) in those who received moxifloxacin (27). Further
human in vivo data are needed to confirm these observations suggesting a low CDI
propensity for omadacycline.
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MATERIALS AND METHODS
Gut model. Three triple-stage chemostat gut models were assembled to simulate CDI, as previously
described (13). Briefly, three glass vessels were arranged in a weir cascade formation, maintained at 37°C,
and pH controlled to represent the proximal (vessel 1, 5.5  0.2), medial (vessel 2, 6.2  0.2), and distal
(vessel 3, 6.8  0.2) human colonic environment (see Fig. S1). Vessel 1 has an operating volume of 280
ml, whereas vessels 2 and 3 operate at 300 ml, and each vessel simulates the nutrient availability and
alkalinity observed in the area of the colon represented. An anaerobic environment is achieved by
sparging the system with nitrogen, and a complex growth medium (13) connected to vessel 1 at a
preestablished rate of 0.015h1 ensures nourishment. The microbial abundance within the gut model
has previously been validated against the intestinal contents of sudden-death victims, and it provides a
close simulation of bacterial activities and composition in different areas of the colon (28). In vivo studies
have shown the distal colon to be severely affected during human CDI (29); thus, in our model, vessel
3 is considered to be most physiologically relevant in terms of propensity to induce CDI. The gut model
has been used to assess in vitro drug efficacy against simulated CDI at various stages of preclinical and
clinical drug development, with data from in vitro models (14, 23) correlating well with data from animal
models and phase 3 clinical trials (30–32).
Experimental design. A gut model experiment (OMC) was conducted to assess the effects of
omadacycline in the intestinal microflora and in C. difficile populations. To confirm the initial observa-
tions, a second assay was later performed. The subsequent experimental design included a new gut
model exposed to omadacycline (OMC1), run in parallel with a gut model dosed with moxifloxacin (MOX)
(Fig. 5). Moxifloxacin is a broad-spectrum fluoroquinolone that has been shown to induce simulated CDI
in vivo (1) and in the gut model (12). It was also the comparator antibiotic chosen for the omadacycline
phase 3 clinical trial and, therefore, was selected as a positive control for the induction of simulated CDI
in this study.
The OMC model was inoculated with fecal emulsion (10% wt/vol in prereduced PBS) prepared from
C. difficile-negative feces of three healthy volunteers, while OMC1 and MOX models were inoculated with
a fecal emulsion prepared from C. difficile-negative feces of five healthy volunteers. All donors were
anonymous, 60 years of age, and with no history of antimicrobial therapy for 3 months.
Following inoculation with fecal emulsion, models were left without intervention for 2 weeks to reach
a steady state (period A). A single 1-ml aliquot of spores (107 CFU/ml) of C. difficile strain 210
(BI/NAP1/PCR ribotype 027/toxinotype III) (23) was inoculated into vessel 1 of each model (period B).
Seven days later, at the start of antimicrobial dosing period, a second inoculum of spores (107 CFU/ml)
was added to vessel 1. A PCR ribotype 027 C. difficile strain was chosen for the study due to the clinical
relevance of this ribotype. The 210 strain was initially isolated in 2005, during a CDI outbreak at the Maine
Medical Centre (Portland, ME) and was kindly supplied by Robert Owens. Clinically relevant antimicrobial
dosages were used during period C. Models OMC and OMC1 were dosed with 430 mg/liter of
omadacycline (once daily, 7 days), while model MOX received 43 mg/liter of moxifloxacin (once daily, 7
days). Antimicrobial dosing was adjusted to achieve the desired concentration in the 280-ml volume of
vessel 1. During a phase 1 clinical trial, 80% of a single oral radiolabeled dose (300 mg) of omadacycline
was excreted in the feces (17). This equated to a maximum fecal omadacycline concentration of 423,000
ngEq/g or 430 mg/Kg (unpublished data). A dosing regimen of 430 mg/liter once daily was therefore
used in this study, equating to 120 mg dosed daily into vessel 1 of the gut model.
The moxifloxacin dosing regimen was performed as previously described (12). Moxifloxacin concen-
tration was based on published data of the concentration of this antimicrobial in human feces. Following
the antimicrobial period, the models were monitored for a further 21 days with no interventions
(period D).
Enumeration of endogenous bacteria, and quantification of C. difficile toxin. Gut microflora
populations were monitored using viable counting on selective and nonselective agars, as described
previously (33). Populations were measured in triplicate (three technical replicates of a single biological
replicate) in vessels 2 and 3 every other day during period A and daily from period B onward. C. difficile
total viable counts (TVC) and spore counts were also monitored daily in vessels 1, 2, and 3 throughout
the experiment (periods A–D). Spore counts were obtained through serial dilution and plating of gut
model fluid after alcohol shock. The C. difficile cytotoxin was monitored from period B onward using a
FIG 5 Outline of the gut model experiments with omadacycline (OMC1) and moxifloxacin (MOX). Asterisks indicate
the period when model OMC1 diverged from MOX. CD, C. difficile spores.
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quantitative Vero cell cytotoxicity assay (33). Cytotoxin titers were correlated to an arbitrary log10 scale
and expressed as relative units (RUs) at the highest dilution, with 70% cell rounding (i.e., 100, 1RU; 101,
2RUs; and 102, 3RUs). The limit of detection was 1.2 log10 CFU/ml for total counts, 1.5 log10 CFU/ml
for spore counts, and 1 RU for toxin titer.
Antimicrobial bioassay. Antimicrobial concentrations in each gut model vessel during periods C
and D were determined using a microbiological bioassay, as described previously (33). Concentrations of
omadacycline were determined using Wilkins-Chalgren agar (Oxoid) with Kocuria rhizophila as the
indicator organism. Concentrations of moxifloxacin were determined using Iso-Sensitest agar (Oxoid)
with Escherichia coli as the indicator organism.
Ethics statement. The collection/use of fecal donations from healthy adult volunteers following
informed consent was approved by the Leeds Institute of Health Sciences and Leeds Institute of Genetics,
Health and Therapeutics and Leeds Institute of Molecular Medicine, University of Leeds joint ethics
committee (reference HSLTLM/12/061).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.01581-18.
SUPPLEMENTAL FILE 1, PDF file, 1.6 MB.
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